18 September 2019

Taking the next step towards access with continued support from the GHIT Fund

The fourth research grant from the Global Health Innovative Technology (GHIT) Fund provides further support for the development, registration and access of a pediatric praziquantel orally dispersible tablet for preschool-age children infected with schistosomiasis.

Despite schistosomiasis being one of the most prevalent parasitic diseases worldwide, preschool-age children are currently left untreated in public health programs due to lack of a suitable pediatric formulation. With the help of the GHIT Fund, the Consortium aims to meet this medical need. With this fourth grant the GHIT Fund reaffirms its confidence in the Consortium’s work towards ensuring affordability, availability and adoption of this new medicine soon.

Read the Consortium’s full press release here.

Read the GHIT Fund press release here.